Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

Finding they were “arbitrary and capricious” under the Administrative Procedures Act, the District Court for the District of Columbia vacated a White House Office of Personnel Management memo and a ...

After delaying a June PDUFA date, the U.S. FDA has approved Kalvista Pharmaceuticals Inc.’s Ekterly (sebetralstat) for hereditary angioedema (HAE) in those aged 12 and older. The plasma kallikrein ...

Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In ...

The first systematic whole genome sequencing study of how chemotherapy damages healthy tissues has shown that many, but not ...

All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, ...

A recent study published in the Journal for Immunotherapy of Cancer has revealed a promising new approach for the treatment ...

The oxidase, cytochrome c, assembly 1-like (OXA1L) gene plays a key role in inserting and assembling proteins in the inner ...

Chinese investigators have published data from studies investigating CYT-997 for the treatment of hypertrophic scars. CYT-997 is a tubulin polymerization inhibitor that reached phase II clinical ...

Brightpath Biotherapeutics Co. Ltd.’s iPS cell-derived BCMA CAR-natural killer T cell therapy candidate has been awarded orphan drug designation by the FDA for the treatment of multiple myeloma.

Shanghai Curegene Pharmaceutical Co. Ltd. has described nucleoside prodrugs reported to be useful for the treatment of viral infections.

Zhuhai Yufan Biotechnologies Co. Ltd. has identified molecular glue degraders comprising an E3 ubiquitin protein ligase-binding agent covalently bound to a DNA-binding protein Ikaros (IKZF1)-targeting ...